<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01277237</url>
  </required_header>
  <id_info>
    <org_study_id>Edin2008-008275-34</org_study_id>
    <secondary_id>2008-008275-34</secondary_id>
    <nct_id>NCT01277237</nct_id>
  </id_info>
  <brief_title>The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease</brief_title>
  <official_title>The Effect Of Omega-3 Fatty Acids on Non-alcoholic Fatty Liver Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Edinburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>NHS Lothian</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Edinburgh</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is preliminary evidence that Omega 3, a compound naturally found in fish oil, reduces
      the amount of fat stored in the liver and improves liver function. The purpose of this study
      is to see whether this observation is correct.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Liver appearance on ultrasound</measure>
    <time_frame>6 months</time_frame>
    <description>The primary endpoint is improvement in grading on ultrasound assessment at six months. Liver brightness and posterior attenuation on ultrasound has previously been shown to correlate significantly with fat scores on liver biopsy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver function tests</measure>
    <time_frame>6 months</time_frame>
    <description>the effect of omega-3 fatty acids on serum liver function tests will be assessed following 6 months of treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>hepatocyte mitochondrial function</measure>
    <time_frame>6 months</time_frame>
    <description>heptocyte mitochondrial function will be measured by breath testing following 6 months of omega-3 supplementation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health-related Quality of Life</measure>
    <time_frame>6 months</time_frame>
    <description>Health related quality of life scores will be compared with baseline following 6 months of omega-3 supplementation</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">50</enrollment>
  <condition>Non Alcoholic Fatty Liver Disease</condition>
  <arm_group>
    <arm_group_label>Omacor</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lactose tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omacor</intervention_name>
    <description>Active comparator: omacor 4g/day</description>
    <arm_group_label>Omacor</arm_group_label>
    <other_name>Omega-3</other_name>
    <other_name>N-3 Fatty acids</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lactose tablet</intervention_name>
    <description>placebo: lactose tablet 4g/day</description>
    <arm_group_label>Lactose tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  a diagnosis of non-alcoholic fatty liver disease

          -  fatty infiltration on ultrasound

          -  abnormal serum liver function tests.

        Exclusion Criteria:

          -  any other identified cause of chronic liver disease

          -  the prescription of medication which would cause non-alcoholic fatty liver - disease
             (e.g. tamoxifen)

          -  already taking supplementary fish oil

          -  alcohol intake of &gt;20g/day for women, &gt;40g/ day for men

          -  known allergy to fish oil

          -  on anticoagulants (antiplatelets are permitted)

          -  severe heart failure (NYHA class IV)

          -  pregnancy/ lactation

          -  age under 18 years.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter C Hayes, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Infirmary of Edinburgh</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Infirmary of Edinburgh</name>
      <address>
        <city>Edinburgh</city>
        <state>Lothian</state>
        <zip>EH164SA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 13, 2011</study_first_submitted>
  <study_first_submitted_qc>January 13, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 14, 2011</study_first_posted>
  <last_update_submitted>January 22, 2014</last_update_submitted>
  <last_update_submitted_qc>January 22, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Non alcoholic fatty liver disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liver Diseases</mesh_term>
    <mesh_term>Fatty Liver</mesh_term>
    <mesh_term>Non-alcoholic Fatty Liver Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

